EA199800443A1 - (имидазол-5-ил) метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу - Google Patents

(имидазол-5-ил) метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу

Info

Publication number
EA199800443A1
EA199800443A1 EA199800443A EA199800443A EA199800443A1 EA 199800443 A1 EA199800443 A1 EA 199800443A1 EA 199800443 A EA199800443 A EA 199800443A EA 199800443 A EA199800443 A EA 199800443A EA 199800443 A1 EA199800443 A1 EA 199800443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
6alkyl
alkyl
6alkyloxy
represents hydrogen
hydroxy
Prior art date
Application number
EA199800443A
Other languages
English (en)
Other versions
EA000710B1 (ru
Inventor
Марк Гастон Вене
Патрик Рене Анжибо
Филипп Мюллер
Жерар Шарль Санз
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Publication of EA199800443A1 publication Critical patent/EA199800443A1/ru
Publication of EA000710B1 publication Critical patent/EA000710B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Настоящее изобретение относится к новым соединениям формулы (I), где пунктирная линия означает необязательную связь; X представляет кислород или серу; Rпредставляет водород, Cалкил, Ar, ArCалкил, хинолинил-Cалкил, пиридил-Cалкил, гидрокси-Cалкил, Cалкилокси-Cалкил, моно- или ди(Cалкил)амино-Cалкил, амино-Cалкил, или радикал формулы -Alk-C(=O)-R, -Alk-S(O)-Rили –Alk-S(O)-R; каждый из R, Rи Rнезависимо представляет водород, гидрокси, галоген, циано, Cалкил, Cалкилокси, гидрокси-Cалкилокси, Cалкилокси Cалкилокси, амино-Cалкилокси, моно- или ди(Cалкил)амино-Cалкилокси, Ar, ArCалкил, Arокси, ArCалкилокси, гидроксикарбонил, Cалкилоксикарбонил, тригалогенметил, тригалогенметокси, Cалкенил; каждый из Rи Rнезависимо представляет водород, галоген, Ar, Cалкил, гидрокси-Cалкил, Cалкилокси-Cалкил, Cалкилокси, Cалкилтио, амино, гидроксикарбонил, Cалкилоксикарбонил, CалкилS(O)Cалкил или CалкилS(O)Cалкил; каждый из Rи Rнезависимо представляет водород, галоген, циано, Cалкил, 4,4-диметилоксазолил, Cалкилокси, или Arокси; Rпредставляет водород, Cалкил, циано, гидроксикарбонил, Cалкилоксикарбонил, Cалкилкарбонил-Cалкил, циано-Cалкил, Cалкилоксикарбонил-Cалкил, карбокси-Cалкил, гидрокси-Cалкил, амино-Cалкил, моно- или ди(Cалкил)амино-Cалкил, имидазолил, галоген-Cалкил, Cалкилокси-Cалкил, аминокарбонил-Cалкил, или радикал формулы -O-R, -S-R, -N-RR; Rпредставляет водород, галоген, циано, Cалкил, Cалкилоксикарбонил, Ar; Rпредставляет водород, Cалкил, Cалкилокси или галоген; Rпредставляет водород или Cалкил; причем указанные соединения обладают активностью, ингибирующей фарнезилтрансферазу; кроме того, настоящее изобретение относится к получению указанных соединений; к композиции, содержащей эти соединения; а также к их использованию в качестве лекарственных средств.Международная заявка была
EA199800443A 1995-12-08 1996-10-16 (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу EA000710B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203427 1995-12-08
PCT/EP1996/004515 WO1997021701A1 (en) 1995-12-08 1996-10-16 Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives

Publications (2)

Publication Number Publication Date
EA199800443A1 true EA199800443A1 (ru) 1998-10-29
EA000710B1 EA000710B1 (ru) 2000-02-28

Family

ID=8220926

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800443A EA000710B1 (ru) 1995-12-08 1996-10-16 (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу

Country Status (36)

Country Link
US (3) US6037350A (ru)
EP (2) EP1162201B1 (ru)
JP (1) JP3257559B2 (ru)
KR (1) KR100272676B1 (ru)
CN (1) CN1101392C (ru)
AP (1) AP1108A (ru)
AR (1) AR004992A1 (ru)
AT (2) ATE215541T1 (ru)
AU (1) AU711142B2 (ru)
BG (1) BG62615B1 (ru)
BR (1) BR9610745A (ru)
CA (1) CA2231105C (ru)
CY (1) CY2289B1 (ru)
CZ (1) CZ293296B6 (ru)
DE (2) DE69635966T2 (ru)
DK (2) DK0865440T3 (ru)
EA (1) EA000710B1 (ru)
EE (1) EE03484B1 (ru)
ES (2) ES2260156T3 (ru)
HK (2) HK1012188A1 (ru)
HR (1) HRP960576B1 (ru)
HU (1) HU221227B1 (ru)
IL (1) IL123568A (ru)
MX (1) MX9802068A (ru)
MY (1) MY114444A (ru)
NO (1) NO314036B1 (ru)
NZ (1) NZ320244A (ru)
PL (1) PL184171B1 (ru)
PT (2) PT865440E (ru)
SI (2) SI1162201T1 (ru)
SK (1) SK283335B6 (ru)
TR (1) TR199800825T2 (ru)
TW (1) TW494101B (ru)
UA (1) UA57717C2 (ru)
WO (1) WO1997021701A1 (ru)
ZA (1) ZA9610254B (ru)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
CN1231215C (zh) 1997-06-02 2005-12-14 詹森药业有限公司 (咪唑－5－基)甲基－2－喹啉酮衍生物用作平滑肌细胞增殖抑制剂
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
EP1097150B1 (en) * 1998-06-16 2004-03-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
US6420555B1 (en) * 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
UA64797C2 (ru) * 1998-07-06 2004-03-15 Янссен Фармацевтика Н.В. Ингибиторы фарнезилтрансферазы как средство для лечения артропатии
EA003877B1 (ru) 1998-07-06 2003-10-30 Янссен Фармацевтика Н.В. Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
ID27562A (id) 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
ATE289602T1 (de) 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
ID29584A (id) * 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
RU2298417C2 (ru) * 1999-11-09 2007-05-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
EP1106612B1 (en) * 1999-11-30 2004-02-11 Pfizer Products Inc. Quinoline derivatives useful for inhibiting farnesyl protein transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2001056552A2 (en) * 2000-02-04 2001-08-09 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
US20030078281A1 (en) * 2000-02-29 2003-04-24 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
US20030022918A1 (en) * 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064197A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP1261374A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1261343A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397425A1 (en) * 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001242434A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030027808A1 (en) * 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397694A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations
CA2397240A1 (en) * 2000-02-29 2001-09-07 Peter Albert Palmer Farnesyl protein transferase inhibitor combinations with camptothecin compounds
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322644A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
EP1322636A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
ES2313991T3 (es) 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
EP1339407B1 (en) * 2000-11-28 2006-04-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
CA2632091C (en) 2000-12-19 2011-03-22 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
DE60119383T2 (de) * 2000-12-27 2007-04-19 Janssen Pharmaceutica N.V. Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
US7129356B2 (en) 2000-12-27 2006-10-31 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
US20040110769A1 (en) * 2001-02-15 2004-06-10 End David William Farnesyl protein transferase inhibitor combinations with antiestrogen agents
AU2002253101B2 (en) * 2001-03-12 2007-08-09 Janssen Pharmaceutica N.V. Process for the preparation of imidazole compounds
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
ES2323265T3 (es) 2001-12-19 2009-07-10 Janssen Pharmaceutica Nv Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
WO2003080058A1 (en) * 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
CN1867334A (zh) * 2003-07-22 2006-11-22 詹森药业有限公司 作为c－fms激酶抑制剂的喹啉酮衍生物
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
AU2004276237B2 (en) 2003-09-23 2008-08-21 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
DE602005021878D1 (de) * 2004-05-03 2010-07-29 Janssen Pharmaceutica Nv Diastereoselektives syntheseverfahren mit 6-brom-4-(3-chlorphenyl)-2-methoxychinolin
EP1758885B1 (en) 2004-05-03 2008-06-18 Janssen Pharmaceutica N.V. Diastereoselective addition of lithiated n-methylimidazole on sulfinimines
CN100567292C (zh) * 2004-05-03 2009-12-09 詹森药业有限公司 制备咪唑化合物的非对映选择性合成方法
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
ME01509B (me) * 2004-11-05 2014-04-20 Janssen Pharmaceutica Nv Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnosti
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN106176584A (zh) * 2005-10-14 2016-12-07 詹森药业有限公司 用于静脉施用的替比法尼制剂
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
JP5089681B2 (ja) 2006-04-20 2012-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤としての複素環式化合物
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016074B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
DK2484696T3 (en) 2006-08-28 2017-10-02 Kyowa Hakko Kirin Co Ltd Antagonistic hLIGHT-specific human monoclonal antibodies
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
JP5330274B2 (ja) 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
JO2959B1 (en) 2007-05-14 2016-03-15 جانسين فارماسوتيكا ان. في Mono-hydrochloric salts for histone dacetylase inhibitor
WO2008144062A1 (en) 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
BRPI0811781A2 (pt) * 2007-05-23 2014-11-11 Allergan Inc Compostos de ((fenil) imidazolil)metilquinolinila terapêuticos.
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
AR069798A1 (es) 2007-12-20 2010-02-17 Novartis Ag Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2358370A2 (en) * 2008-11-13 2011-08-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
NZ593090A (en) * 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ME01573B (me) 2009-05-12 2014-09-20 Addex Pharma Sa DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2547661A2 (en) 2010-03-16 2013-01-23 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2806112C (en) 2010-07-28 2023-03-21 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 ***-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
JP6059731B2 (ja) 2011-10-28 2017-01-11 ノバルティス アーゲー 新規プリン誘導体および疾患の処置におけるその使用
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
ES2673847T3 (es) 2012-07-25 2018-06-26 Celldex Therapeutics, Inc. Anticuerpos anti KIT y usos de los mismos
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
SI2909192T1 (sl) 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Metilensko vezani kinolinilni modulatorji za ROR-gama-t
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
LT2925888T (lt) 2012-11-28 2018-01-10 Merck Sharp & Dohme Corp. Vėžio gydymo kompozicijos ir būdai
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
CN112695039A (zh) 2013-08-26 2021-04-23 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
AU2014334616A1 (en) 2013-10-15 2016-04-28 Janssen Pharmaceutica Nv Quinolinyl modulators of RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
EP3076969B1 (en) 2013-12-06 2021-09-01 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
SI3431106T1 (sl) 2014-01-21 2021-03-31 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
ES2863074T3 (es) 2014-06-04 2021-10-08 Biontech Res And Development Inc Anticuerpos monoclonales humanos contra el gangliósido GD2
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP2018517673A (ja) 2015-04-21 2018-07-05 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ロナファルニブおよびリトナビルを含む医薬組成物
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP6630742B2 (ja) 2015-08-17 2020-01-15 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
WO2017034877A1 (en) * 2015-08-27 2017-03-02 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
CA3006769A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
CN110234639A (zh) * 2016-12-08 2019-09-13 杭州领业医药科技有限公司 替吡法尼的晶型及其制备方法及药物组合物
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11542244B2 (en) 2018-05-18 2023-01-03 Kura Oncology, Inc. Synthesis of tipifarnib
EP3824287A1 (en) 2018-07-20 2021-05-26 Pierre Fabre Médicament Receptor for vista
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2023102378A1 (en) * 2021-11-30 2023-06-08 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
WO2023141082A1 (en) * 2022-01-20 2023-07-27 Teva Czech Industries S.R.O. Solid state forms of tipifarnib and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them

Also Published As

Publication number Publication date
CN1203598A (zh) 1998-12-30
EA000710B1 (ru) 2000-02-28
ZA9610254B (en) 1998-06-05
PL325962A1 (en) 1998-08-17
US6169096B1 (en) 2001-01-02
AP1108A (en) 2002-10-02
TW494101B (en) 2002-07-11
CZ157398A3 (cs) 1998-10-14
DE69620445D1 (de) 2002-05-08
EE03484B1 (et) 2001-08-15
KR100272676B1 (ko) 2000-11-15
HK1042482A1 (en) 2002-08-16
HK1042482B (zh) 2006-06-09
DK1162201T3 (da) 2006-07-17
BG62615B1 (en) 2000-03-31
WO1997021701A1 (en) 1997-06-19
ES2260156T3 (es) 2006-11-01
SK283335B6 (sk) 2003-06-03
CN1101392C (zh) 2003-02-12
CY2289B1 (en) 2003-07-04
NO980927L (no) 1998-06-08
ATE321757T1 (de) 2006-04-15
DE69620445T2 (de) 2002-12-12
HUP9900185A3 (en) 1999-11-29
HRP960576B1 (en) 2002-04-30
HUP9900185A2 (hu) 1999-04-28
EP1162201A9 (en) 2002-04-03
EP1162201B1 (en) 2006-03-29
NO314036B1 (no) 2003-01-20
PL184171B1 (pl) 2002-09-30
JP3257559B2 (ja) 2002-02-18
SI0865440T1 (en) 2002-08-31
AP9801257A0 (en) 1998-06-30
JPH10511405A (ja) 1998-11-04
BR9610745A (pt) 1999-07-13
MX9802068A (es) 1998-08-30
US6420387B1 (en) 2002-07-16
DE69635966D1 (de) 2006-05-18
US6037350A (en) 2000-03-14
IL123568A0 (en) 1998-10-30
ES2175137T3 (es) 2002-11-16
UA57717C2 (ru) 2003-07-15
DK0865440T3 (da) 2002-07-22
HRP960576A2 (en) 1998-02-28
BG102458A (en) 1999-06-30
EE9800146A (et) 1998-10-15
ATE215541T1 (de) 2002-04-15
EP1162201A2 (en) 2001-12-12
PT865440E (pt) 2002-09-30
DE69635966T2 (de) 2006-11-30
CA2231105C (en) 2005-09-13
EP0865440B1 (en) 2002-04-03
TR199800825T2 (xx) 1998-08-21
EP0865440A1 (en) 1998-09-23
EP1162201A3 (en) 2003-11-26
AR004992A1 (es) 1999-04-07
AU7294896A (en) 1997-07-03
MY114444A (en) 2002-10-31
SK70498A3 (en) 1998-10-07
HU221227B1 (en) 2002-08-28
HK1012188A1 (en) 1999-07-30
NZ320244A (en) 1999-06-29
IL123568A (en) 2001-08-08
SI1162201T1 (sl) 2006-08-31
PT1162201E (pt) 2006-08-31
CA2231105A1 (en) 1997-06-19
KR19990063891A (ko) 1999-07-26
NO980927D0 (no) 1998-03-04
CZ293296B6 (cs) 2004-03-17
AU711142B2 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
EA199800443A1 (ru) (имидазол-5-ил) метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
EA199800395A1 (ru) Производные 2-хинолона, ингибирующие фарнезилтрансферазу
BR9803883A (pt) Derivado de amida.
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
HUP0004238A2 (hu) Farnezil-transzferáz inhibitor hatású imidazolszármazékok és eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
TR199700727T1 (xx) Farnesil transferaz�n�n yeni inhibit�rleri.
MY115339A (en) Compositions containing micronized nebivolol
BE902897A (fr) Derives 3-aminopropoxyaryliques, leur preparation leur application comme medicaments et compositions pharmaceutiques les contenant
ES2170864T3 (es) Comprimidos que contienen una resina de intercambio de aniones.
NO954072D0 (no) Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
DE60117847D1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
ID22045A (id) Senyawa-senyawa trisiklik yang berguna untuk penghambatan fungsi protein-g dan untuk pengobatan penyakit-penyakit proliferatif
ATE292117T1 (de) Zusammensetzungen zur behandlung von hautkrankheiten
DE69819539D1 (de) Antithrombotische mittel
HK1053109A1 (en) Substituted homopiperidinyl benzimidazole compounds, pharmaceutical compositions comprising the same, methods for preparing them and the use for the preparation of a medicament of them
HK1023346A1 (en) Novel substituted tetrahyropyridine derivatives, method of preparation and pharmaceutical compositions containing them
NO973401L (no) Kortikosteroidinneholdende sammensetninger og fremstilling derav
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU